Pharma News
Lupin to expand US generics business with Gavis acquisition
Indian generics manufacturer Lupin Pharmaceuticals (Lupin) announced on 23 July 2015 that it had entered into a definitive agreement to acquire US generics makers Gavis Pharmaceuticals and Novel Laboratories (Gavis).
Acquisitions for Endo and Strides
Endo Pharmaceuticals (Endo) and Strides Arcolab (Strides) are both looking at acquisitions as a way to expand their generics businesses.
Amneal to acquire Australian generics business from Actavis
Privately held US generics maker Amneal Pharmaceuticals (Amneal) announced on 31 March 2015 that it had made a deal with the Australian subsidiary of Actavis to acquire the Australian generics business of Actavis for an undisclosed amount.
Anticompetitive acquisition forces generics sale
US generics maker CorePharma has had to sell its rights of two generics in order to merge with fellow US drug company Impax Laboratories (Impax). The US Federal Trade Commission (FTC) ruled that Impax’s acquisition of CorePharma would have been anticompetitive unless CorePharma sold its rights and assets for pilocarpine, a drug used to treat dry mouth and glaucoma, and ursodiol, a treatment for liver and gall bladder diseases.
Teva finally makes bid for Mylan
In the wake of many rumours, Israeli generics giant Teva Pharmaceutical Industries (Teva) finally announced on 21 April 2015 that it had made a bid for US-based generics maker Mylan.
Growing investment in Vietnam
Cyprus-based generics company Medochemie is building its second factory in Vietnam. Construction on the site, which will occupy 44,700 square metres, is expected to be completed by the end of 2015 with operations commencing in early 2016.
Teva to buy Auspex Pharma, reinforcing CNS portfolio
Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 30 March 2015 that it would buy US biopharmaceutical company Auspex Pharmaceuticals (Auspex) for an equity value of US$3.5 billion.
India to set up pharma manufacturing clusters
The Indian Government is planning to set up pharmaceutical manufacturing clusters in order to reduce costs and make the industry more competitive.
Boehringer Ingelheim loses patent battle with India’s Cipla
German pharmaceutical company Boehringer Ingelheim (Boehringer) has lost its patent on the Spiriva respiratory drug in India. The Indian patent office has agreed with the Indian drugmaker Cipla that Boehringer’s Spiriva patent was obvious and was not an invention under India’s patent laws.
Indian Government to launch own brand of generics
Not happy with its current control over the price of drugs in the country, the Indian Government has announced plans to launch its own brand of low cost generics.
